Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay.

ABSTRACT:

Background

Clinical outcomes in high-grade glioma (HGG) have remained relatively unchanged over the last 3 decades with only modest increases in overall survival. Despite the validation of biomarkers to classify treatment response, most newly diagnosed (ND) patients receive the same treatment regimen. This study aimed to determine whether a prospective functional assay that provides a direct, live tumor cell-based drug response prediction specific for each patient could accurately predict clinical drug response prior to treatment.

Methods

A modified 3D cell culture assay was validated to establish baseline parameters including drug concentrations, timing, and reproducibility. Live tumor tissue from HGG patients were tested in the assay to establish response parameters. Clini

SUBMITTER: Shuford S 

PROVIDER: S-EPMC8207705 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature